TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LEXETTE

HALOBETASOL PROPIONATE
Approved 2018-05-24
Jump to: Indications Approvals Trials Competitors Safety Patents
2
Indications
--
Phase 3 Trials
7
Years on Market

Details

Status
Discontinued
First Approved
2018-05-24
Routes
TOPICAL
Dosage Forms
AEROSOL, FOAM

Companies

MAYNE PHARMA
Active Ingredient: HALOBETASOL PROPIONATE

LEXETTE Approval History

Loading approval history...

What LEXETTE Treats

2 FDA approvals

Originally approved for its first indication in 2018 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEXETTE FDA Label Details

Pro

LEXETTE Patents & Exclusivity

Latest Patent: May 2037

Patents (3 active)

US10857159*PED Expires May 30, 2037
US11020407 Expires Nov 30, 2036
US10857159 Expires Nov 30, 2036
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA210566 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.